drugset
drugset / Trial / NCT02035215

Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia

NCT02035215 ↗

Phase 3 Unknown 80 enrolled Kuhnil Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of combination therapy of omega-3-acids ethylesters 90/Atorvastatin calcium in type Ⅱb hyperlipidemia

Timeline

Start
2014-01
Primary completion
2014-10
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Omega-3-acids ethylesters 90 Unknown 4 g Oral
Background Atorvastatin Small molecule 20 mg Oral

Indications

familial hyperlipidemia